Annexon Biosciences granted inducement stock options to two new non-executive employees, totaling 705,000 shares at an exercise price of $4.64 per share. These options have a ten-year term and vest over four years, with 25% vesting after one year and the remainder monthly thereafter, contingent on continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and supports Annexon's growth in developing targeted immunotherapies for neuroinflammatory diseases. The grant reflects the company's strategy to attract talent critical to advancing its therapeutic platform.
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
